Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 26, 1-18, February 1, 1966]
© 1966 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davis, A. P.
Right arrow Articles by Shimkin, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davis, A. P.
Right arrow Articles by Shimkin, M. B.

Evaluation of Chemotherapeutic Agents in Mammary Carcinoma Induced by 3-Methylcholanthrene in Wistar Rats1

A. P. Davis, M. Gruenstein and M. B. Shimkin

( Fels Research Institute, Temple University School of Medicine, Philadelphia, Pennsylvania)

Forty-five nonhormonal agents were tested for antitumor activity against mammary carcinoma induced by gastric instillations of 3-methylcholanthrene (NSC-21970) in female Wistar rats. Animals given the potential antitumor agent (T) were compared to untreated (C) or ovariectomized (O) controls, by determining T/C and T/O values for inhibition of tumor volume and of development of additional tumors. Judged by both criteria, the agents produced the following responses: At Day 14, discounting groups of rats with excessive mortality due to the drug, 17 of 43 compounds were active compared with untreated controls (T/C of 0.5 or less). Two of these compounds were also active compared with ovariectomized controls. At Day 42, five of 41 agents were active compared with untreated controls: NSC-1026 (1-aminocyclopentanecarboxylic acid), NSC-3425 (6-azauracil), NSC-9698 (mannitol mustard), NSC-19893 (5-fluorouracil), and NSC-23519 (5-diazouracil). None were more effective than ovariectomy, and only NSC-1026 and 9698 produced inhibition approximately equal to that produced by ovariectomy.

1 Supported by contract SA-43-ph-4344 from the Cancer Chemotherapy National Service Center, National Cancer Institute, National Institutes of Health, Public Health Service.




This article has been cited by other articles:


Home page
NeurologyHome page
J. Fueyo, C. Gomez-Manzano, W.K.A. Yung, T. J. Liu, R. Alemany, J. M. Bruner, S. K. Chintala, J. S. Rao, V. A. Levin, and A. P. Kyritsis
Suppression of human glioma growth by adenovirus-mediated Rb gene transfer
Neurology, May 1, 1998; 50(5): 1307 - 1315.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1966 by the American Association for Cancer Research.